RxMP Therapeutics is a company that is developing novel systemically delivered hemostatic agents that are designed to arrest or prevent excessive bleeding, thereby improving health care outcomes and costs and reducing the need for transfused blood. They are working on developing a primary treatment for excessive bleeding that is more effective than transfusion which is expensive and blood supplies are often limited; the cost of transfusions and associated complications total approximately $27 billion in the United States each year.
Location: United States, Florida, Miami
Employees: 1-10
Investors 1
| Date | Name | Website |
| - | Florida In... | florida-in... |